'Dual antiplatelet therapy' diaporamas de présentation

Challenging Cases in Perioperative Medicine

Challenging Cases in Perioperative Medicine. Margaret M. Beliveau MD General Internal Medicine Mayo Clinic, Rochester, Mn. Disclosures. No relevant industry conflict of interest I will not be discussing off-label use of drugs

2.04k views • 136 slides

Oxford

749 views • 46 slides

COMPREHENSIVE META-ANALYSIS ON ORAL ANTICOAGULANTS FOR THE SECONDARY PREVENTION OF CORONARY ARTERY DISEASE INCLUDING MOR

COMPREHENSIVE META-ANALYSIS ON ORAL ANTICOAGULANTS FOR THE SECONDARY PREVENTION OF CORONARY ARTERY DISEASE INCLUDING MORE THAN 50,000 PATIENTS.

588 views • 43 slides

A Pooled Analysis of the REAL-LATE and the ZEST-LATE Trial

Duration of Dual Antiplatelet Therapy After Drug-Eluting Stent Implantation . A Pooled Analysis of the REAL-LATE and the ZEST-LATE Trial . Seung-Jung Park, MD, PhD, University of Ulsan College of Medicine, Asan Medical Center on behalf of the REAL-LATE and the ZEST-LATE trial .

768 views • 30 slides

High Tech - Marseille 25 au 27 janvier 2011 Marie-Claude MORICE, MD, FESC, FACC Massy, France

412 views • 29 slides

Myeong-Ki Hong , MD. Ph D, on behalf of RESET investigators Professor, Division of Cardiology, Severance Cardiovascula

A New Strategy for Discontinuation of Dual Antiplatelet Therapy: Real Safety and Efficacy of 3-Month Dual Antiplatelet Therapy Following Zotarolimus-Eluting Stent Implantation: RESET Trial . Myeong-Ki Hong , MD. Ph D, on behalf of RESET investigators Professor, Division of Cardiology,

429 views • 28 slides

Duration of Dual Antiplatelet Therapy

Duration of Dual Antiplatelet Therapy. European and US Guidelines. PCI-CURE CV Death or MI. CHARISMA Instantaneous Hazard for Moderate or Severe Bleeding. CHARISMA Primary End Point. TRILOGY-ACS Primary Efficacy End Point to 30 Months (Age < 75 years). DAPT Trial Total Enrollment .

559 views • 21 slides

Trial Vignettes

Trial Vignettes . TRITON-TIMI 38 ARMYDA 4 + 5 OPTIMA. Cameron G Densem. NO CONFLICT OF INTEREST TO DECLARE. TR ial to Assess I mprovement in T herapeutic O utcomes by Optimizing Platelet Inhibitio N with Prasugrel- TIMI 38. Dual antiplatelet therapy Limitations of Clopidogrel

473 views • 21 slides

Rationale for Study

Combining warfarin and antiplatelet therapy after coronary stenting in the Global Registry of Acute Coronary Events: is it safe and effective to use just one antiplatelet agent?.

715 views • 16 slides

368 views • 13 slides

235 views • 4 slides

PRODIGY

PRODIGY. Objective Assess the efficacy and safety of prolonged dual antiplatelet therapy (DAPT) with aspirin and clopidogrel after coronary stenting, compared with currently recommended DAPT regimens Study Design Open-label, three-center, randomized, factorial assignment

383 views • 3 slides

RESOLUTE US

RESOLUTE US. One-Year Clinical Outcomes from the Pivotal Multicenter RESOLUTE US Study. Objective To evaluate the clinical effectiveness of the Resolute zotarolimus-eluting stent (R-ZES) in a US population SUBJECTS 1,402 patients with de novo lesions in native coronary arteries

137 views • 3 slides

A Possible Algorithm for Surgery

83 views • 1 slides